Drug Profile
Research programme: Enterococcus monoclonal antibodies - Dyax/Inhibitex
Alternative Names: Anti-enterococci therapeutics - Dyax/Inhibitex; Enterococcal Mabs - Dyax/InhibitexLatest Information Update: 13 Jul 2009
Price :
$50
*
At a glance
- Originator Dyax; Inhibitex
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Enterococcal infections
Most Recent Events
- 13 Jul 2009 Discontinued - Preclinical for Enterococcal infections in USA (unspecified route)
- 21 Aug 2007 Preclinical development is ongoing
- 13 Apr 2006 This programme is still in active development